Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a…

By R. Haddad, A. O'neill, G. Rabinowits, R. Tishler, F. Khuri, D. Adkins, Joseph I. Clark, N. Sarlis, J. Lorch, J. Beitler and 3 more. The Lancet Oncology, 2013

635 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/8945a61bc920c7dd444b838511e58b9f0b438d86

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. El-Deiry
2. K. Higgins
3. C. Steuer
4. N. Saba
5. J. Parks

Citations in the corpus

• An update on larynx cancer (2017, background): “However, toxicity was higher with induction therapy, with 52 serious adverse events versus 22 in the CRT arm.(80) Given the high risk of recurrence in patients with advanced SCCHN and the potential benefits of induction therapy, the DeCIDE trial (docetaxel-based CRT with or without induction chemoth”